Get started
Author

Paula Elizabeth Keating

Observed names: P Keating, P. Keating, PAULA KEATING, Paula E. Keating, Paula Keating
Observed institutions: University of Massachusetts Chan Medical School, Christchurch Hospital, Victoria University of Wellington, Canterbury Health Laboratories, Dublin City University, Health New Zealand, University of Edinburgh
ORCID: 0000-0001-8166-8819
Observed ORCID: 0000-0001-8166-8819
OpenAlex ID: A5073754952
Maternal Thyroid-Blocking Immunoglobulins in Congenital Hypothyroidism*
1990 · ROSALIND S. BROWN, PAULA KEATING, et al. · The Journal of Clinical Endocrinology & Metabolism · 38
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab
2015 · Barry D. Hock, Lisa K. Stamp, et al. · Therapeutic Drug Monitoring · 31
Patterns of major histocompatibility complex class II expression on T cell subsets in different immunological compartments 1. Expression on resting T cells
1993 · Bernadette M. Dutia, Ian McConnell, et al. · European Journal of Immunology · 28
HMGCR ‐associated myositis: a New Zealand case series and estimate of incidence
2016 · N. Kennedy, P. Keating, et al. · Internal Medicine Journal · 24
Evidence for the expression of two distinct MHC class II DRβ like molecules in the sheep
1994 · B M Dutia, I McConnell, et al. · Animal Genetics · 22
Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay
2018 · Barry D. Hock, Judith L. McKenzie, et al. · Therapeutic Drug Monitoring · 17
Protection from EAE by IL‐4Rα−/− macrophages depends upon T regulatory cell involvement
2009 · Paula Keating, David O'Sullivan, et al. · Immunology and Cell Biology · 14
Infliximab and adalimumab concentrations and anti‐drug antibodies in inflammatory bowel disease control using New Zealand assays
2018 · Murray L. Barclay, Shwan Karim, et al. · Internal Medicine Journal · 13
Deletion of IL-4Rαin the BALB/c mouse is associated with altered lesion topography and susceptibility to experimental autoimmune encephalomyelitis
2014 · Jacqueline M. Orian, Paula Keating, et al. · Autoimmunity · 9
Anti‐ HMGCR autoantibodies in self‐limiting statin‐induced myopathy
2017 · Paula Keating, Joanna Young, et al. · International Journal of Rheumatic Diseases · 8
PDF
Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand
2024 · Ke Li Chow, Paula Elizabeth Keating, et al. · Seminars in Arthritis and Rheumatism · 7
Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa/New Zealand
2024 · Ke Li Chow, Paula Elizabeth Keating, et al. · Rheumatology · 7
PDF
Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum
2019 · Barry D. Hock, Stewart M. Smith, et al. · Journal of Immunological Methods · 7
HMGCR autoantibody testing: two tiers required
2021 · Ke Li Chow, Paula Elizabeth Keating, et al. · Pathology · 5
PDF
The optimisation of a novel iodide microassay and its application in an immunoassay for human antibody levels in serum
1993 · R. O'Kennedy, P. Keating · Journal of Immunological Methods · 4
Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study
2024 · Lisa K. Stamp, Paula Keating, et al. · The Journal of Rheumatology · 3
PDF
Response to: New immunoassays for anti-HMG-CoA reductase antibodies may lead to incorrect diagnosis in inflammatory myositis
2018 · Paula Keating, Mark Van Voorthuizen, et al. · Pathology · 3
FRI0395 Incidence of myositis-specific autoantibody (MSA) specificities in sera referred to new zealand (NZ) medical laboratories
2017 · J O'donnell, P Keating, et al. · Annals of the Rheumatic Diseases · 3
PDF
Four‐year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing
2023 · Paula E. Keating, Barry D. Hock, et al. · Internal Medicine Journal · 2
Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study
2022 · Ke Li Chow, Paula Elizabeth Keating, et al. · Pathology · 2
PDF
Anti-pneumococcal antibody measurement: implications of discordance between second and third generation assays
2020 · Caroline L.M. Allan, Paula E. Keating, et al. · Pathology · 2
Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay
2020 · Paula E. Keating, Roderick Duncan, et al. · Pathology · 2
PDF
Use and detection of nonradioactive lodine-labeled antibodies for immunoassay
1991 · Richard O'Kennedy, Paula Keating · Analytical Biochemistry · 2
Development of a non-radioactive iodine label-based method for the determination of proteolytic activity
1991 · Paula Keating, Fiona Anderson, et al. · The Analyst · 2
Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
2024 · Paula Elizabeth Keating, Barry D. Hock, et al. · Therapeutic Drug Monitoring · 1
Works count: 38
Citation count: 258
H-index: 9
I10-index: 8
Year
Topic
Type